This work is licensed under a Creative Commons Attribution 4.0 International License.
MCo-polyR-L1
General Information
DCTPep ID DCTPep00629
Peptide Name MCo-polyR-L1
Sequence CRRKRRRCRRDSDCPGACICRGNGYCGSGSDGGV
Sequence Length 34
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Cancer targeted peptides
Activity Information
| Cell Line | Disease | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|
| HT-29 | Colon adenocarcinoma | IC50>100 μM | MTT assay | 48h | 1 |
| MCF-7 | Invasive breast carcinoma of no special type | IC50>100 μM | MTT assay | 48h | 1 |
| PC-3 | Prostate carcinoma | IC50>100 μM | MTT assay | 48h | 1 |
Hemolytic Activity Human red blood cells: no hemolytic activity(as show in Fig.4)
Normal (non-cancerous) Cytotoxicity HUVEC: IC50>100 μM
Target pigment epithelium-derived factor; somatostatin
Affinity Not available
Mechanism Not available
Structure Information
PDB ID Not available
Predicted Structure DCTPep00629
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Cyclic
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C139H238N60O46S6
Absent amino acids EFHLMQTW
Theoretical pI 9.48
Acidic residues 3
Basic residues 9
Polar residues 18
Molecular weight (Average) 3678.15
Molecular weight (Monoisotopic) 3675.65
Common amino acids R
Net charge 6
Instability index (II) 100.16
Aliphatic index 22.94
Grand average of hydropathicity (GRAVY) -1.074
Half Life
1.2 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Extinction coefficients
Ext. coefficient 1865
Abs 0.1% (=1 g/l) 0.507, assuming all pairs of Cys residues form cystines
Ext. coefficient 1490
Abs 0.1% (=1 g/l) 0.405, assuming all Cys residues are reduced
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 27734947
Title Dual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy
Year 2016
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.